Abstract
A novel schedule of 5-fluorouracil administration has been developed for biochemical modulation studies. In combination with the pyrimidine synthesis inhibitor PALA, 5-fluorouracil has been given as a 24-hour infusion, repeated weekly: a dose of 2600 mg/m2 is well tolerated. To identify a suitable dose of 5-fluorouracil as a single agent on this schedule, we treated 26 patients at doses ranging from 2800 to 3400 mg/m2 per week. Two-thirds of the patients had failed previous therapy, and most were symptomatic from their disease. Over half of the patients had metastatic colorectal cancer. The dose-limiting toxicity was diarrhea: Grade 3 or 4 toxicity occurred at every level tested. Twenty-two of the 26 patients required therapy interruption because of toxicity. The severity of this toxicity indicated that escalation of 5-fluorouracil on this schedule beyond the 2600 mg/m2 known to be tolerated in the PALA-containing regimen, would be impractical. Two patients, both with previously untreated colorectal cancer, had partial remissions lasting three and five months respectively. This dose-intense schedule of 5-fluorouracil administration will be explored further in large-scale randomized trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Seifert P, Baker L, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123–128, 1975
Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H, Cornell G. A Phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 39:34–40, 1977
Lokich JJ, Bothe H, Fine N, Perri J. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565–2568, 1981
Caballero GA, Ausman RK, Quebbeman EJ. Long-term ambulatory continuous intravenous infusion of 5-fluorouracil for the treatment of advanced adenocarcinoma. Cancer Treat Rep 69:13–15, 1985
O'Dwyer PJ, Comis RC. Schedule as a determinant of cytotoxic anticancer drug activity. Current Opinion in Oncology 1:174–178, 1989
Cohen AM, Shank B, Friedman MA. Colorectal Cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology. Lippincott, Philadelphia, 1989, pp. 895–964.
Hansen R, Ryan L, Anderson T, Quebbeman E, Haller D. A Phase III trial of bolus 5-FU versus protracted infusion 5-FU +/− cisplatin in metastatic colorectal cancer. An Eastern Cooperative Oncology Group study (EST-2286). Proc Am Soc Clin Oncol 11:171, 1992
Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. Arandomized trial of cisplatin + 5-fluorouracil infusion and cisplatin + 5-fluorouracil bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56:2740–2744, 1985
Ardalan B, Singh G, Silberman H. Arandomized Phase I and II study of short-term infusion of high-dose fluorouracil with or with N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6:1053–1058, 1988
O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL. Phase II study of Biochemical Modulation of 5-Fluorouracil by low-dose PALA in patients with colorectal cancer. Journal of Clinical Oncology 8:1497–1503, 1990
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47:207–214, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haas, N.B., Hines, J.B., Hudes, G.R. et al. Phase I trial of 5-fluorouracil by 24-hour infusion weekly. Invest New Drugs 11, 181–185 (1993). https://doi.org/10.1007/BF00874152
Issue Date:
DOI: https://doi.org/10.1007/BF00874152